Nguyen TQ et al., 2025-07-31: In nude mice carrying A549 lung tumours, oral fenbendazole 40 mg/kg with DADA 100 mg/kg produced 50% complete tumour regression versus 11.1% with DADA alone and 0% with fenbendazole alone, and the combination outperformed cisplatin 5 mg/kg.
In the animal model, combined treatment with 100 mg/kg DADA and 40 mg/kg FZ resulted in a 50% reduction in complete tumor regression, compared to 11.1% and 0% in the single-agent treatment groups, respectively.
Nguyen TQ et al., 2025-07-31: In nude mice carrying A549 lung tumours, oral fenbendazole 40 mg/kg with DADA 100 mg/kg produced 50% complete tumour regression versus 11.1% with DADA alone and 0% with fenbendazole alone, and the combination outperformed cisplatin 5 mg/kg. C3 lung (nearest primary study). Study type: animal (BALB/c nude mice, A549 xenograft), 8 groups, 6-10 mice each, 60-day observation; country Vietnam (University of Science and Technology of Hanoi, Military Medical Academy) with USC; doses FZ 40 mg/kg/day oral, DADA 20 or 100 mg/kg/day oral, cisplatin 5 mg/kg daily intraperitoneal; funder not listed in the abstract; conflicts not stated in the abstract; maker not stated; comparators: healthy control, tumour control, cisplatin, each single agent. IMPORTANT: the partner drug is DADA (vitamin B15), not ivermectin, and the response figure is 50%, not 85% – see C4. Also filed as FBA-26 (claims C3, C4). Study type: animal.
